These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 16076281

  • 1. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
    Guo X, Saini HK, Wang J, Gupta SK, Goyal RK, Dhalla NS.
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):717-32. PubMed ID: 16076281
    [Abstract] [Full Text] [Related]

  • 2. Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
    Guo X, Wang J, Elimban V, Dhalla NS.
    Can J Physiol Pharmacol; 2008 Apr; 86(4):139-47. PubMed ID: 18418421
    [Abstract] [Full Text] [Related]

  • 3. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 4. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 5. Effect of high salt intake on local renin-angiotensin system and ventricular dysfunction following myocardial infarction in rats.
    de Resende MM, Mill JG.
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):274-9. PubMed ID: 17324137
    [Abstract] [Full Text] [Related]

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 7. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Sep; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 8. Role of subcellular remodeling in cardiac dysfunction due to congestive heart failure.
    Babick AP, Dhalla NS.
    Med Princ Pract; 2007 Sep; 16(2):81-9. PubMed ID: 17303941
    [Abstract] [Full Text] [Related]

  • 9. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM, Böhm M.
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [Abstract] [Full Text] [Related]

  • 10. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

  • 11. Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction.
    Dai W, Kloner RA.
    Postgrad Med; 2011 Mar 15; 123(2):49-55. PubMed ID: 21474893
    [Abstract] [Full Text] [Related]

  • 12. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Mar 15; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 13. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG, Schencking M, Scheer C, Rupp H.
    Praxis (Bern 1994); 1997 Apr 02; 86(14):566-74. PubMed ID: 9198851
    [Abstract] [Full Text] [Related]

  • 14. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May 02; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

  • 15. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S, Narula J, Marelli C, Cesario D.
    Am J Cardiol; 2006 Mar 15; 97(6):921-5. PubMed ID: 16516603
    [Abstract] [Full Text] [Related]

  • 16. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.
    Connelly KA, Advani A, Advani S, Zhang Y, Thai K, Thomas S, Krum H, Kelly DJ, Gilbert RE.
    Cardiovasc Ther; 2013 Apr 15; 31(2):84-91. PubMed ID: 21884026
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 15; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 15; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 19. On target to dual block RAS?
    Papadopoulos DP, Papademetriou V, Makris TK.
    Angiology; 2009 Mar 15; 60(6):739-49. PubMed ID: 19144653
    [Abstract] [Full Text] [Related]

  • 20. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH.
    J Card Fail; 2002 Dec 15; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.